 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 May 1998 | Volume 128 Issue 9 | Pages 713-720
Background: In contrast to most observational studies, the randomized Physicians' Health Study found no association between aspirin use and colorectal cancer after 5 years.
Objective: To determine the effect of randomly assigned aspirin treatment and self-selected aspirin use on the incidence of colorectal cancer after 12 years and to identify factors influencing the self-selection of regular aspirin use.
Design: Randomized clinical trial and prospective cohort study.
Setting: Male physicians throughout the United States.
Patients: 22 071 healthy male physicians who were 40 to 84 years of age in 1982.
Intervention: 325 mg of aspirin every other day. In 1988, the aspirin arm of the randomized trial was stopped early. Participants then chose to receive either aspirin or placebo for the rest of the study.
Measurements: Annual questionnaires asking about aspirin use and other variables, including occurrence of cancer.
Results: Colorectal cancer was diagnosed in 341 patients during the study period. Over 12 years of follow-up, random assignment to aspirin was associated with a relative risk for colorectal cancer of 1.03 (95% CI, 0.83 to 1.28). Various gastrointestinal symptoms and diagnoses were strong predictors of less frequent aspirin use in 1988. The relative risk for colorectal cancer in persons who used aspirin frequently after 1988 was 1.07 (CI, 0.75 to 1.53).
Conclusions: In the Physicians' Health Study, both randomized and observational analyses indicate that there is no association between the use of aspirin and the incidence of colorectal cancer. The low dose of aspirin used and the short treatment period may account for the null findings. However, other characteristics associated with the use of aspirin in observational studies remain a plausible alternative explanation.
Author and Article Information
From Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts; and University of Ulm, Ulm, Germany.
ARTICLE
Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study
Acknowledgments: The authors thank the study participants for their collaboration and the BASF Corp. and Bristol-Meyers Products for logistic support. They also thank the staff of the Physicians' Health Study, particularly Vadim Bubes, Fran LaMotte, Sally Skinner, and Martin Van Denburgh.
Grant Support: In part by research grants CA-34944, CA-40360, HL-26490, and HL-34595 from the National Institutes of Health; grant D/96/17743 from the German Academic Exchange Service (Dr. Sturmer); and grant 823B-33287 from the Swiss National Science Foundation (Dr. Sturmer).
Requests for Reprints: Charles H. Hennekens, MD, DrPH, Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215.
Current Author Addresses: Dr. Sturmer: University of Ulm, Department of Epidemiology, Albert-Einstein-Allee 43, D-89081 Ulm, Germany.
This article has been cited by other articles:
|
|
 |
|
  J. Jankowski and R. Hunt Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 1858 - 1861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Hall, J. E. Chavarro, I-M. Lee, W. C. Willett, and J. Ma A 22-year Prospective Study of Fish, n-3 Fatty Acid Intake, and Colorectal Cancer Risk in Men Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1136 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Weiss, T. D. Koepsell, and B. M. Psaty Generalizability of the Results of Randomized Trials Arch Intern Med, January 28, 2008; 168(2): 133 - 135. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sturmer, J. E. Buring, and R. J. Glynn Aspirin and Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: Weighing the Evidence Ann Intern Med, November 6, 2007; 147(9): 674 - 674. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Logan Commentary: Preventing colorectal cancer with aspirin what next? Int. J. Epidemiol., October 5, 2007; (2007) dym204v1. [Full Text] [PDF]
|
|
|
|
|
|
E. Flossmann and P. M Rothwell Commentary: Aspirin and colorectal cancer an epidemiological success story Int. J. Epidemiol., October 1, 2007; 36(5): 962 - 965. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Martinez and E. R. Greenberg More Aspirin for Less Cancer? J Natl Cancer Inst, April 18, 2007; 99(8): 582 - 583. [Full Text] [PDF]
|
|
|
|
|
|
C. Dube, A. Rostom, G. Lewin, A. Tsertsvadze, N. Barrowman, C. Code, M. Sampson, and D. Moher The Use of Aspirin for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force Ann Intern Med, March 6, 2007; 146(5): 365 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Hall, H. Campos, H. Li, H. D. Sesso, M. J. Stampfer, W. C. Willett, and J. Ma Blood Levels of Long-Chain Polyunsaturated Fatty Acids, Aspirin, and the Risk of Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 314 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sturmer, J. E. Buring, I-M. Lee, J. M. Gaziano, and R. J. Glynn Metabolic Abnormalities and Risk for Colorectal Cancer in the Physicians' Health Study Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2391 - 2397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mahipal, K. E. Anderson, P. J. Limburg, and A. R. Folsom Nonsteroidal Anti-inflammatory Drugs and Subsite-Specific Colorectal Cancer Incidence in the Iowa Women's Health Study. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1785 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Allison, C. Garland, R. Chlebowski, M. Criqui, R. Langer, L. Wu, H. Roy, A. McTiernan, L. Kuller, and for the Women's Health Initiative Investigators The Association between Aspirin Use and the Incidence of Colorectal Cancer in Women Am. J. Epidemiol., September 15, 2006; 164(6): 567 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Sansbury, R. C. Millikan, J. C. Schroeder, P. G. Moorman, K. E. North, and R. S. Sandler Use of Nonsteroidal Antiinflammatory Drugs and Risk of Colon Cancer in a Population-based, Case-Control Study of African Americans and Whites Am. J. Epidemiol., September 15, 2005; 162(6): 548 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Cook, I-M. Lee, J. M. Gaziano, D. Gordon, P. M Ridker, J. E. Manson, C. H. Hennekens, and J. E. Buring Low-Dose Aspirin in the Primary Prevention of Cancer: The Women's Health Study: A Randomized Controlled Trial JAMA, July 6, 2005; 294(1): 47 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Sangha, M Yao, and M M Wolfe Non-steroidal anti-inflammatory drugs and colorectal cancer prevention Postgrad. Med. J., April 1, 2005; 81(954): 223 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Sivak-Sears, J. A. Schwartzbaum, R. Miike, M. Moghadassi, and M. Wrensch Case-Control Study of Use of Nonsteroidal Antiinflammatory Drugs and Glioblastoma Multiforme Am. J. Epidemiol., June 15, 2004; 159(12): 1131 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P J Hu, J Yu, Z R Zeng, W K Leung, H L Lin, B D Tang, A H C Bai, and J J Y Sung Chemoprevention of gastric cancer by celecoxib in rats Gut, February 1, 2004; 53(2): 195 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Lieberman, S. Prindiville, D. G. Weiss, and W. Willett Risk Factors for Advanced Colonic Neoplasia and Hyperplastic Polyps in Asymptomatic Individuals JAMA, December 10, 2003; 290(22): 2959 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Wang, J. Q. Huang, G. F. Zheng, S. K. Lam, J. Karlberg, and B. C.-Y. Wong Non-steroidal Anti-inflammatory Drug Use and the Risk of Gastric Cancer: A Systematic Review and Meta-analysis J Natl Cancer Inst, December 3, 2003; 95(23): 1784 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sample, M. Wargovich, S. M. Fischer, N. Inamdar, P. Schwartz, X. Wang, K.-A. Do, F. A. Sinicrope, N. E. Day, D. E. G. Shuker, et al. A Dose-finding Study of Aspirin for Chemoprevention Utilizing Rectal Mucosal Prostaglandin E2 Levels as a Biomarker Cancer Epidemiol. Biomarkers Prev., March 1, 2002; 11(3): 275 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Ladabaum, C. L. Chopra, G. Huang, J. M. Scheiman, M. E. Chernew, and A. M. Fendrick Aspirin as an Adjunct to Screening for Prevention of Sporadic Colorectal Cancer: A Cost-Effectiveness Analysis Ann Intern Med, November 6, 2001; 135(9): 769 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.R. Paterson and J.R. Lawrence Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer QJM, August 1, 2001; 94(8): 445 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Janne and R. J. Mayer Chemoprevention of Colorectal Cancer N. Engl. J. Med., June 29, 2000; 342(26): 1960 - 1968. [Full Text] [PDF]
|
|
|
|
|
|
H-H. S. Chow, D. L. Earnest, D. Clark, N. Mason-Liddil, C. B. Kramer, J. G. Einspahr, J. M. Guillen-Rodriguez, D. J. Roe, W. Malone, J. A. Crowell, et al. Effect of Subacute Ibuprofen Dosing on Rectal Mucosal Prostaglandin E2 Levels in Healthy Subjects with a History of Resected Polyps Cancer Epidemiol. Biomarkers Prev., April 1, 2000; 9(4): 351 - 356. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. McCaskill-Stevens, E. T. Hawk, P. J. Flynn, and S. M. Lippman National Cancer Institute-Supported Cancer Chemoprevention Research: Coming of Age J. Clin. Oncol., November 1, 1999; 17(90001): 53 - 62. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Potter Colorectal Cancer: Molecules and Populations J Natl Cancer Inst, June 2, 1999; 91(11): 916 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Chemoprophylaxis for Colon Cancer? Journal Watch (General), May 8, 1998; 1998(508): 2 - 2. [Full Text]
|
|
Article
